Related Experiment Video
Updated: Dec 29, 2025
10:28
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
Published on: May 24, 2018
16.2K
Author Correction: Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents
Paul M Ryan1,2,3, Elaine Patterson1,3, Robert M Kent1,2
1Teagasc Food Research Centre, Moorepark, Fermoy, Co, Cork, Ireland.
Scientific Reports
|February 7, 2020
Abstract:
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
767
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
767
01:23Dipeptidyl Peptidase 4 Inhibitors
497
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
497